Posts by Follicle Thought
Follicum Announces Data From Phase 2A Scalp Trial
(Updated Below) As the company promised to do earlier this month, Follicum has released data from its phase 2a study which concluded in August earlier this year. This was the first trial Follicum conducted using FOL-005, a modified peptide, on human scalps. In this recent scalp study, five doses (including placebo) were evaluated where patients…
Read MoreHairClone Featured In Consulting Room Article
One of the most fascinating companies in the hair restoration industry, HairClone, has been featured in the latest edition of the UK’s Consulting Room online magazine. The article features commentary from HairClone CEO Paul Kemp PhD and Medical Director Dr. Bessam Farjo. The article by Lorna Jackson is very detail oriented and provides a comprehensive…
Read MoreFollicum To Present Phase 2 Data In October 2018
According to its latest news update, Follicum will present top-line data from its recent phase 2a trial by the end of the month. The phase 2a trial for Follicum’s hair growth candidate FOL-005 was completed at sites in Hamburg and Berlin, Germany at the end of August this year. The study comprised 60 patients (assumed…
Read MoreIt’s Official: Trinov Is Coming In 2018
Updated After a long wait we finally have the answer. The “Brotzu Lotion” aka Trinov is going to be released by Fidia Pharma this year. The press release shown above was posted on Fidia’s official website today only in the Italian version. The key points from the announcement are as follows: Production on Trinov has…
Read MoreHairClone September 2018 Newsletter
British hair-cell cloning company HairClone has released its latest newsletter on September 10th. This is the second newsletter of the year from HairClone, the company previously published a newsletter in February. HairClone typically divides its news updates into two categories, business and science. It’s interesting to follow HairClone’s progress in these regards and see how…
Read MoreDrug WAY-316606 To Move Ahead With Pharma Company
The Guardian has reported the intriguing drug WAY-316606, which was originally developed for osteoporosis, may soon be entering human hair growth clinical trials with the help of an Italian pharmaceutical company. I was pleasantly surprised to find some worthwhile information in the latest “mainstream media baldness cure” article published by The Guardian today. I should…
Read MoreFollicum Completes Phase 2A With Data To Follow
Another important milestone has been achieved by the Swedish biotech company Follicum. Today, Follicum announced that all patients participating in their phase 2a clinical trial have completed treatment. The phase 2a trial took place at centers in Berlin and Hamburg, Germany and was carried out over the past 3 months. 60 subjects participated and received…
Read MoreSamumed’s Moving Into Phase 3
It looks like we may have another approved treatment on the market within the next 2 years. Today, Samumed released a newsletter addressing its program for androgenic alopecia, and stated that the company “has conducted an Investigator Meeting to initiate our upcoming 625-patient Phase 3 clinical trial.” While the results from the phase 2 trial…
Read MoreAlexey Terskikh of SBP Launches New Hair Cloning Company
About 3.5 years ago the Sanford Burnham Prebys medical research institute released an article that received major attention in the hair seeker community and in the mainstream media. SBP researcher Alexey Terskikh PhD had just published a peer reviewed article detailing his work turning human embryonic stem cells (hESCs) into hair-producing dermal papillae cells. It…
Read MoreNew Beauty Hair Solutions Article Tidbits
New Beauty, a magazine covering the female aesthetics industry, has released a print article featuring “hair loss solutions.” The article contains quotes and information from Dr. George Cotsarelis, RiverTown Therapeutics, and Histogen. The Brotzu Lotion is also mentioned, though with information already known. Setipiprant For Females In the article, Dr. Cotsarelis shares that his lab…
Read More